211 related articles for article (PubMed ID: 24734312)
1. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia.
Tuteja S; Duffy D; Dunbar RL; Movva R; Gadi R; Bloedon LT; Cuchel M
Pharmacotherapy; 2014 Mar; 34(3):227-39. PubMed ID: 24734312
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects.
Patel G; King A; Dutta S; Korb S; Wade JR; Foulds P; Sumeray M
J Clin Pharmacol; 2016 Jan; 56(1):47-55. PubMed ID: 26120010
[TBL] [Abstract][Full Text] [Related]
3. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.
Davis KA; Miyares MA
Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757
[TBL] [Abstract][Full Text] [Related]
4. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
5. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
[TBL] [Abstract][Full Text] [Related]
6. Lomitapide for the treatment of hypercholesterolemia.
Berberich AJ; Hegele RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1261-1268. PubMed ID: 28598687
[TBL] [Abstract][Full Text] [Related]
7. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
8. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
Stefanutti C
Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
[TBL] [Abstract][Full Text] [Related]
10. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
[TBL] [Abstract][Full Text] [Related]
11. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
Roeters van Lennep J; Averna M; Alonso R
J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
[TBL] [Abstract][Full Text] [Related]
12. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
[TBL] [Abstract][Full Text] [Related]
13. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.
Davidson MH; Donovan JM; Misir S; Jones MR
Am J Cardiovasc Drugs; 2010; 10(5):305-14. PubMed ID: 20860413
[TBL] [Abstract][Full Text] [Related]
14. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
Perry CM
Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
[TBL] [Abstract][Full Text] [Related]
15. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.
Cuchel M; Meagher EA; du Toit Theron H; Blom DJ; Marais AD; Hegele RA; Averna MR; Sirtori CR; Shah PK; Gaudet D; Stefanutti C; Vigna GB; Du Plessis AM; Propert KJ; Sasiela WJ; Bloedon LT; Rader DJ;
Lancet; 2013 Jan; 381(9860):40-6. PubMed ID: 23122768
[TBL] [Abstract][Full Text] [Related]
17. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
[TBL] [Abstract][Full Text] [Related]
18. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
[TBL] [Abstract][Full Text] [Related]
19. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
